Vera Therapeutics, Inc.

  • Safety Score
  • Market Cap $1.21B
  • PE -7
  • Debt $50.91M
  • Cash $55.09M
  • EV $1.21B
  • FCF -$156.41M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$175.46M
EBIT-$178.23M
ROE-33%
ROA-29%
FCF-$156.41M
Equity$535.00M
Growth Stability1
PE-6.91
PB2.27
P/FCF-7.75
Price/Cash0.05
Debt/Equity0.1
Debt/FCF-0.33
Equity CAGR60%
Earnings Growth YoY82%
Earnings Growth QoQ19%
Equity CAGR 5Y62%
Equity CAGR 3Y93%
Market Cap$1.21B
Assets$610.17M
Total Debt$50.91M
Cash$55.09M
Shares Outstanding63.67M
EV1.21B
Safety Score65%
Working Capital584.18M
Current Ratio27.68
Shares Growth 3y40%
Equity Growth QoQ-7%
Equity Growth YoY51%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

SEC Filings

Direct access to Vera Therapeutics, Inc. (VERA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2025
    • 10-Q Mar 31
  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Vera Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Vera Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Vera Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Vera Therapeutics, Inc..

= -$1.6B
012345678910TV
fcf-$156M-$156M-$156M-$156M-$156M-$156M-$156M-$156M-$156M-$156M-$156M-$1.6B
DCF-$142M-$129M-$118M-$107M-$97M-$88M-$80M-$73M-$66M-$60M-$603M
Value-$1.6B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/202012/202112/202212/202312/2024TTM
Net Margins------
ROA--39%-68%-55%-23%-29%
ROE--47%-116%-94%-26%-33%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/202012/202112/202212/202312/2024TTM
Debt over FCF--0.17-0.37-0.54-0.37-0.33
Debt over Equity-00.070.330.490.090.1
Growth Stability-----1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth------
Earnings YoY growth--39%173%8%59%-
Equity YoY growth--178%11%32%468%62%
FCF YoY growth--18%136%36%47%-